Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates

International Journal of Gynecological Pathology

Volumn 25, Issue 2, 2006, Pages 131-139

  Surowiak, Pawel ^a,b,c   Materna, Verena ^a   Drag Zalesinska, Małgorzata ^b   Wojnar, Andrzej ^c   Kaplenko, Irina ^d   Spaczyński, Marek ^d   Dietel, Manfred ^a   Zabel, Maciej ^b,d   Lage, Hermann ^a  

^a Charité Campus Benjamin Franklin Medical Center   (Germany)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c 4th Department of Internal Medicine and Pulmonology   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Cisplatin; Immunohistochemistry; Maspin; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; ANTINEOPLASTIC AGENT; MASPIN; SERINE PROTEINASE INHIBITOR;

ADULT; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; CYTOREDUCTIVE SURGERY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LAPAROTOMY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGED; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; OVARY; OVARY TUMOR; PATHOLOGY; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

AGED; ANTINEOPLASTIC AGENTS; CELL NUCLEUS; CISPLATIN; CYTOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; SERPINS; SURVIVAL RATE;

EID: 33747188108     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pgp.0000183050.30212.2f     Document Type: Article

References (22)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics. CA Cancer J Clin 2002;52:23-47.
2. Stewart BW, Kleihues P. World Cancer Report. Lyon, France: IARC Press; 2003.
3. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19:3-10.
4. Averette HE, Hoskins W, Nguyen HN, et al. National survey of ovarian carcinoma. 1. A patient care evaluation study of the American College of Surgeons. Cancer 1993;71:1629-38.
5. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
6. Baker EK, El-Osta A. The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res 2003;290:177-94.
7. Koul S, McKiernan JM, Narayan G, et al. Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. Mol Cancer 2004;3:1-12.
8. Castagna A, Antonioli P, Astner H, et al. A proteomic approach to cisplatin resistance in the cervix squamous cell line A431. Proteomics 2004;4:3246-67.
9. Ogasawara S, Maesawa C, Yamamoto M, et al. Disruption of cell-type-specific methylation at the maspin gene promoter is frequently involved in undifferentiated thyroid cancers. Oncogene 2003;23:1117-24.
10. Streuli CH. Maspin is a tumour suppressor that inhibits breast cancer tumour metastasis in vivo. Breast Cancer Res 2002;4:137-40.
11. Sood AK, Fletcher MS, Gruman LM, et al. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 2002;8:2924-32.
12. Materna V, Liedert B, Thomale J, et al. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int J Cancer 2005;115:393-402.
13. Kowalski P, Surowiak P, Lage H. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/Pgp, MRP2, and BCRP. Mol Ther 2005;11:1393-8.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumours. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
15. UICC. TNM Classification of Malignant Tumors. New York: Wiley-Liss; 1997.
16. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of a universal grading system of ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998;82:893-901.
17. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987;8:138-40.
18. Latha K, Zhang W, Cella N, et al. Maspin mediates increased tumor cell apoptosis upon induction of the mitochondrial permeability transition. Mol Cell Biol 2005;25:1737-48.
19. Murakami J, Asaumi J, Maki Y, et al. Effects of demethylating agent 5-aza-2,-deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines. Oral Oncol 2004;40:597-603.
20. Balch C, Huang TH, Brown R, et al. The epigenetics of ovarian cancer drug resistance and resensitisation. Am J Obstet Gynecol 2004;191:1552-72.
21. McKay JA, Williams EA, Mathers JC. Folate and DNA methylation during in utero development and aging. Biochem Soc Trans 2004;32:1006-7.
22. Pufulete M, Al-Ghnaniem R, Rennie JA, et al. Influence of folate status on genomic DNA methylation in colonic mucosa of subjects without colorectal adenoma or cancer. Br J Cancer 2005;1:1-5.